ArticleTherapeutic advances in drug safety2025

Notch pathway inhibition with crenigacestat (LY3039478) in a phase I first-in-human clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia.

Jean-Marie Michot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.